Outcomes in 24 selected patients with stage IVB cervical cancer and excellent performance status treated with radiotherapy and chemotherapy
- 24 November 2006
- journal article
- Published by Springer Nature in Radiation Medicine
- Vol. 24 (9) , 625-630
Abstract
We sought to review outcomes in patients with stage IVB carcinoma of the cervix treated with irradiation in combination with chemotherapy. We report outcomes of 24 consecutive patients with good performance status treated from 1998 to 2005. Most of these patients underwent concurrent irradiation with platinum-based chemotherapy. Some patients received subsequent systemic chemotherapy. All patients underwent external beam radiotherapy; 7 patients (29%) had additional high-dose-rate and 12 (50%) low-dose-rate brachytherapy. Two patients (8%) received an IMRT boost instead of brachytherapy. The mean dose to point A was variable (73.9 ± 19.2 Gy). Twenty patients (83%) received radio-sensitizing platinum-based chemotherapy, and the remaining had radiotherapy alone. Seven patients (29%) had further combination chemotherapy. Therapy was well tolerated. The overall survival was 44% at 36 months and 22% at 5 years. Patients with stage IVB cervical cancer have mostly been treated with palliative intent. With the advent of concurrent chemoradiation, we have treated many of these cases with aggressive combination therapy. In this series, the use of radiotherapy and multiagent chemotherapy in patients with stage IVB cervical carcinoma and good performance status was well tolerated and resulted in higher survival rates than previously reported.Keywords
This publication has 22 references indexed in Scilit:
- Randomized Phase III Trial of Cisplatin With or Without Topotecan in Carcinoma of the Uterine Cervix: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2005
- Combination chemotherapy of docetaxel and carboplatin in advanced or recurrent cervix cancer. A pilot studyGynecologic Oncology, 2005
- Phase III Study of Cisplatin With or Without Paclitaxel in Stage IVB, Recurrent, or Persistent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2004
- Phase II study of topotecan and paclitaxel for recurrent, persistent, or metastatic cervical carcinomaGynecologic Oncology, 2004
- Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysisThe Lancet, 2001
- First-Line Chemotherapy with Paclitaxel and Platinum for Advanced and Recurrent Cancer of the Cervix—A Phase II StudyGynecologic Oncology, 1999
- Outcome of recurrent cervical carcinoma following definitive irradiationGynecologic Oncology, 1989
- Revised FIGO staging for gynaecological cancerBJOG: An International Journal of Obstetrics & Gynaecology, 1989
- Phase II Studies of Bleomycin, Cyclophosphamide, Doxorubicin and Cisplatin, and Bleomycin and Cisplatin in Advanced Cervical CarcinomaAmerican Journal of Clinical Oncology, 1988
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958